>Insilico said it’s currently not interested in pursuing clinical trials for the potential drug; it’ll leave that for other researchers to follow now that the molecule has been publicly identified. Instead, the main purpose of the study was to serve as a “proof of concept” of what is now possible with AI, said Alán Aspuru-Guzik, a professor of computer science and chemistry at U of T, director of the Acceleration Consortium and the co-principal investigator who led the study.

So there won’t be any follow up with this drug.